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Alzheimer’s diseaseA summary of the recently published efforts on tacrine derivatives as a renewed potential therapeutic
approach for the treatment of Alzheimer’s disease is presented.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.Alzheimer’s disease (AD) is the most prominent form of demen-
tia in the world affecting about 6% of the population aged over 65,
its incidence increasing with age.1 Despite enormous efforts to elu-
cidate the pathophysiology of AD, the disease is still incurable.2 AD
is clinically characterized by memory impairment and progressive
deﬁcits in different cognitive domains related to a pronounced
degradation of the cholinergic system and to alterations in the
glutamatergic and serotoninergic systems.3 The cholinergic hypoth-
esis of AD4 asserts that the decline of the acetylcholine (ACh) level
leads to cognitive and memory deﬁcits, and that sustaining or
recovering the cholinergic function is therefore supposed to be
clinically beneﬁcial.5 ACh can be degraded by two types of cho-
linesterases (ChEs), namely acetylcholinesterase (AChE) and butyr-
ylcholinesterase (BuChE). Indeed, nowadays AD therapy is mainly
founded on AChE inhibitors (AChEIs), able to increase ACh levels
in the cholinergic synapses.6 Thus, the number of approved drugs
is limited to only three AChEIs, the moderately active drugs riv-
astigmine, donepezil and galantamine, and the NMDA antagonist
memantine. Unfortunately, instead of curing or preventing neuro-
degeneration, AChEIs only enable a palliative treatment,7 and their
clinical effectiveness is still under debate.8Because of the multifactorial nature of AD, the traditional ‘one
molecule, one target’ paradigm, the so-called magic bullets, can
generally only offer limited and transient beneﬁts. Thus, a strategy
named multi-target-directed ligand (MTDL)9 has recently
emerged,10,11 targeting compounds decorated with additional
pharmacological/biochemical properties other than ChE inhibition,
being able to bind simultaneously to different receptors or enzy-
matic systems involved in the disease.
Many aspects of the etiology and pathological pathways of AD
remain unclear and subject to speculation. These pathological
lesions have been considered to be the causative features of AD,
giving rise to several theories about AD pathogenesis, mostly
including the b-amyloid cascade12 and tau13 hypotheses, oxidative
stress, free radical formation and neuroinﬂammation.14
In this complex scenario, tacrine (1, Fig. 1), the most potent and
clinically effective AChEI,15 was approved for clinical use by the
U.S. FDA in 1993. However, it soon exhibited hepatotoxicity via
elevation of serum alanine aminotransferase levels, resulting in lim-
ited clinical application and, consequently, was withdrawn from
the pharmaceutical market shortly after its approval.16 This is the
reason why tacrine is usually considered not a gold standard for
AD drug discovery. In fact, although new AChEIs continue to be
developed, more recent efforts have been aimed at developing
small molecules that target the underlying pathogenic mecha-
nisms of AD. These new approaches, and the fact that most of
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Figure 1. Structures of tacrine (1), (Z)-3-(4-chlorophenyl)-N0-((4-chlorophenyl)sulfonyl)-N-methyl-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamide (2), and xanom-
eline (3).
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itor programs, currently make AChEI drug discovery less relevant
from a medicinal chemistry perspective.
It is the purpose of this BMCL Digest to update the most recent
reports on this topic, showing the, unexplored possibilities of such
drugs.17a
Tacrine (1) (Fig. 1) has been widely used in the past and in more
recent studies to design hybrid or multi-target compounds in order
to combine its potent AChE inhibition with other pharmacological
properties. This is achieved by covalently connecting tacrine to
other pharmacologically active structures,17b such (Z)-3-(4-chloro-
phenyl)-N0-((4-chlorophenyl)sulfonyl)-N-methyl-4-phenyl-4,5-
dihydro-1H-pyrazole-1-carboximidamide (2), a CB1 receptor
antagonist (Fig. 1),18 and xanomeline (3) (Fig. 1), a M1 agonist.19
In addition, the key and critical point was to demonstrate that
the newly-designed tacrine molecules were not hepatotoxic, while
retaining other beneﬁcial cholinergic properties.
As a consequence, several tacrine derivatives have been re-
ported, including:
Bis(7)tacrine dimer (4, Fig. 2),20a which exhibited a 1000-fold
higher AChE inhibition potency than the reference drug, dual
interaction in the active and peripheral sites of AChE, AChE-
induced Ab aggregation through interaction with its peripheral
anionic site21 and neuroprotective effects related to the interaction
with b-secretase enzyme, NMDA and GABA receptors.22 Very
recently, Bolognesi et al., have reported 4,40-bis[(1,2,3,4-tetrahy-
droacridin-9-yl)aminomethyl]biphenyl (5, Fig. 2) as a new bis(7)-
tacrine MTDL ligand showing activity against AChE and amyloid
formation and aggregation.20b
Cystamine-tacrine dimer (6, Fig. 2), endowed with a lower tox-
icity in comparison to bis(7)tacrine dimer (4), able to inhibit AChE/
BuChE, self- and AChE-induced Ab aggregation in the same range of
tacrine, exerts a neuroprotective action on the SH-SY5Y neuroblas-
toma cell line against H2O2-inducedoxidative injury.23
Tacrine-ferulic acid hybrid (7, Fig. 2), is a moderate antioxidant
and potent reversible, non-competitive AChEI able to bind the PAS
of the AChE, showing an almost equipotent capacity to inhibit
EeAChE (IC50 = 4.4 ± 1.7 lM) and eqBuChE (IC50 = 6.7 ± 1.6 lM).24
Conversely, kinetic measurements for BuChE showed reversible
and competitive inhibition by hybrid 7, revealing that this tacrine
derivative competes for the same active site as acetylcholine.
Antioxidant agents tacrine-ferulic acid-nitric oxide (NO) donor
hybrids, such as compound 8 (Fig. 2),25 being ﬁvefold and twofold
more active than the parent product 7 toward AChE/BuChE, respec-
tively. In the vascular relaxation assay, inhibitor 8 possessed an
activity comparable to the activity of the reference drug isosorbide
dinitrate (ISDN). Tested in the scopolamine-induced cognition ani-
mal model, tacrine derivative 8 showed signiﬁcant cognitive
improvements. In addition, hepatotoxicity studies conﬁrmed that
8 was much safer than tacrine. Altogether, the multifunctionaleffects of the new hybrid 8 might be considered a promising lead
compound.
Non-toxic tacrine-organic nitrates26a are tacrine hybrid com-
pounds with NO-donating nitrate connected to the tacrine scaf-
fold via an alkylenediamine-type linker. All compounds
inhibited ChEs. Target compound 9, in particular, showed 7- to
8-fold higher AChE inhibitory activity compared to tacrine, and
moderately relaxed the porcine pulmonary arteries in in vitro
vasorelaxation experiments, aided by the NO donor part of the
molecule. In the in vivo hepatotoxicity studies, tacrine, but not
compound 9, showed serious hepatotoxicity. These results sug-
gest that these NO donor-tacrine hybrids, especially compound
9, may be considered to be novel, more potent and safer anti-Alz-
heimer’s drugs. Nitric oxide (NO) is an essential signaling mole-
cule involved in various physiological functions in humans.26b
The over and under production of NO is responsible for a number
of pathological conditions. The biosynthesis of NO by brain neuro-
nal NOS (nNOS) is associated with stroke and chronic neurode-
generative diseases, such as Alzheimer’s, Parkinson’s, and
Huntington’s diseases.26c
Tacrine-silibinin co-drug (10, Fig. 2), showed high AChE and
BuChE inhibition, neuroprotective effects, lacking tacrine’s hepato-
toxicity in vitro and in vivo, with the same pro-cognitive effects
in vivo as tacrine, being superior to the physical mixture of tacrine
and silibinin in all these regards.27
Mercapto-tacrine hybrids such as compound 1128 (Fig. 2), en-
dowed with cholinesterase inhibition, long-term potentiation
enhancement, neuroprotective activity and less hepatotoxicity,
are consequently good candidates for further studies directed to-
ward the development of novel drugs for age-related neurodegen-
erative diseases such as AD.
Particularly interesting among all the tacrine derivatives stud-
ied and investigated is the case of 7-MEOTA (9-amino-7-meth-
oxy-1,2,3,4-tetrahydroacridine) (12, Fig. 2), an old Czech
cholinergic drug ﬁrst synthesized by Patocka,29 a potent, cen-
trally-active ChEI, free of the serious side effects related to ta-
crine.30–32 In single-administration studies, 7-MEOTA was well
tolerated, and thus further research efforts are currently aimed at
improving its pharmacological proﬁle.33 In connection with the re-
sults obtained previously,34 fourteen new N-alkyl 7-MEOTA ana-
logue hydrochlorides, which were found to be less toxic than
tacrine, were synthesized.34b Their activity in vitro on AChE and
BuChE showed inhibitory power on a micromolar scale. The inhib-
itory proﬁle and selectivity index for hAChE of the new compounds
were compared to standards of tacrine and 7-MEOTA. Compound
13 (Fig. 2) showed the best selectivity ratio for AChE
(IC50 = 0.10 lM, which is ﬁvefold more potent than tacrine). The
molecular docking with compound 13 showed that the 7-MEOTA
moiety was bound to the active site cleft between Trp86 and
Tyr337 by p–p stacking in the PAS anionic aromatic site.
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Figure 2. Structure of tacrine derivatives and hybrid compounds (4–14).
1918 A. Romero et al. / Bioorg. Med. Chem. Lett. 23 (2013) 1916–1922It is interesting to highlight tacrine derivative 14 (Fig. 2), a high-
afﬁnity, ﬂuorescent cholinesterase inhibitor able to bind to amy-
loid structures, described by Gütschow and co-workers.35
In the search for more effective tacrine derivatives, Tang et al.,36
designed a series of hybrids of tacrine-oxoisoaporphine. These
compounds exhibit high AChE inhibitory activity with IC50 values
in the nanomolar range in most cases, the most potent being com-
pound 15 (IC50 EeAChE = 3.4 ± 0.2 nM) (Fig. 3), clearly more potent
than tacrine. Interestingly, all the synthesized compounds pre-
sented a good inhibitory potency on self-induced Ab1–42 aggrega-
tion and the AChE-induced Ab1–40 aggregation, being more
potent than tacrine and curcumin.Using the same strategy, tacrine-caffeic acid hybrids were de-
signed as multifunctional agents for AD treatment.37 Among these,
the hybrid 16 (Fig. 3) showed the highest selectivity in inhibiting
AChE over BuChE, suggesting that this tacrine binds to both cata-
lytic and peripheral anionic sites (CAS, PAS) of AChE, has low tox-
icity and Cu2+-chelating properties as well as neuroprotective
effects against two oxidative stress inducers, H2O2 and glutamate,
in the prevention of cell death in HT22, a mouse hippocampal cell
line. Furthermore, compound 16 also inhibited self- or AChE-in-
duced Ab1–40 aggregation. Taken together, this hybrid compound
may represent a valuable anti-AD candidate for further
development.
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Figure 3. Novel tacrine-based hybrids (15–24).
A. Romero et al. / Bioorg. Med. Chem. Lett. 23 (2013) 1916–1922 1919Another example of this strategy is represented by tacrine-mel-
atonin hybrids.38 Molecular modeling studies showed that these
hybrids target both the CAS and PAS of AChE. In order to evaluate
the pharmacological proﬁle, compounds 17 and 18 (Fig. 3) were
more potent and selective hAChEIs than tacrine, with IC50 in the
subnanomolar range. These compounds showed interesting neuro-
protective properties against several toxic insults such as rotenone,
H2O2 and Ab25–35 peptide in the human neuroblastoma SH-SY5Y
cell line. They also displayed an important inhibitory potency on
self-induced Ab peptide aggregation and the AChE-induced Ab
peptide aggregation. Finally, they exhibited low toxicity and may
be able to penetrate the CNS, according to an in vitro parallel arti-
ﬁcial membrane permeability assay for the blood–brain barrier
(PAMPA-BBB) analysis.39 All these new tacrine—melatonin hybridscan be considered interesting structures in the search for new
agents of potential application in AD.
O-Hydroxyl- or O-amino benzylamine-tacrine heterodimers40
were obtained by reacting N-(aminoalkyl)tacrine with salicylic
aldehyde or derivatives of 2-aminobenzaldehyde. Relative to ta-
crine, which had an IC50 value of 109 nM, a selection of these hy-
brids were potent as hAChEIs with IC50 values in the nano- and
subnanomolar range, and also exhibited very good BuChE inhibi-
tory activities (nanomolar range). Among the synthesized com-
pounds, compound 19 (Fig. 3) exhibited the greatest inhibitory
potency towards AChE (IC50 = 0.55 nM). All the hybrids have poten-
tial complexation abilities for biometals such as Cu2+, Fe2+, and Zn2+,
and in addition, most of them showed antioxidative activity as well
as a favorable effect on Ab1–42 peptide aggregation inhibition.
1920 A. Romero et al. / Bioorg. Med. Chem. Lett. 23 (2013) 1916–1922Recently, a series of multipotent phenylthiazole-tacrine hybrids
has been reported.41 Screening results showed that these com-
pounds were potent inhibitors of AChE and BuChE, and they efﬁ-
ciently prevented Ab1–42 self-aggregation. Furthermore,
compounds 20 and 21 (Fig. 3) displayed the blockade effect on
Ca2+ overload in the primary cultured cortical neurons. This block-
ing could represent a valuable strategy for preventing cell death,
and consequently, phenylthiazole-tacrine hybrids will have an
additional biological property for the therapy of AD.
In this line, a new series of tacrine-multialkoxybenzene hybrids
was designed.42a All the tested compounds, an particularly hybrid
22 (IC50 EeAChE = 7.98 ± 0.12 nM) (Fig. 3), showed signiﬁcant ChEs
inhibitory activity and 1- to 11.5-fold of inhibition selectivity for
BuChE over AChE, which were similar to or better than those of ta-
crine. This is important, since as AChE is the abundant form of cho-
linesterases in the brain, the role of BuChE has been usually
overlooked. However, during the development of AD, BuChE activ-
ity increases by 40–90%42b in the most affected brain areas such as
the temporal cortex and hippocampus, while at the same time
AChE activity declines. Moreover, high levels of BuChE are found
to have a role in Ab aggregation during the early stages of senile
plaque formation as well as in other pathological characteristics
of AD.42b Therefore, inhibition of BuChE, not only AChE, may have
clinical beneﬁts in treating symptoms and alleviating the manifes-
tation of neurodegenerative diseases and dementia.42b The new
hybrids could bind to both the CAS and PAS of AChE, in good agree-
ment with the results of molecular modeling studies. These hy-
brids also prevented Ab1–42 self-aggregation with percentages of
inhibition higher than the reference compound, curcumin.
Tacrine-phenylbenzoheterocyclic hybrids43 are excellent multi-
functional drug candidates for AD. Particularly, compound 23
(Fig. 3) was the most potent EeAChE mixed-type inhibitor
(IC50 = 0.017 ± 0.002 lM), 18-fold more potent than tacrine, dem-
onstrating also similar Ab aggregation inhibitory activity to that
of curcumin. These results indicate that these new tacrine deriva-
tives are useful templates for the development of new multifunc-
tional anti-AD drugs.
Tacrine-8-hydroxyquinoline hybrids44 have interesting and
noteworthy in vitro biological activity for the treatment of AD.
Thus, they exhibit: (1) hAChE and hBuChE inhibition with IC50 val-
ues in the nano- and subnanomolar range; (2) inhibited AChE-in-
duced Ab aggregation; (3) signiﬁcant antioxidant properties in an
oxygen radical absorbance capacity (ORAC) assay, being more po-
tent than the reference compound, trolox (vitamin E analogue);
(4) high neuroprotective activity, based on LDH release, against
damage caused by mitochondrial free radicals; (5) selective com-N NH
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Figure 4. Tacrine-baseplexation for Cu2+, showing low cellular toxicity, and (6) capability
to penetrate the CNS, according to the PAMPA-BBB test. Particu-
larly, compound 24 (Fig. 3) was shown to be a potent dual inhibitor
of human AChE (IC50 = 20 ± 1 nM) and BuChE. (IC50 = 5.0 ± 0.2 nM),
antioxidant capacity in the ORAC test (3.3 ± 0.01 lM of Trolox
equivalents/lM of tested compound), 3.3-fold more potent than
the vitamin E analogue, propidium displacement of 22%, perme-
ability to the brain–blood-barrier (BBB) by passive diffusion, com-
plexed Cu (II) cations, and neuroprotection power showing
negligible cell death using rotenone as toxic insult.44
Recently, Incerti et al., described a series of tetrahydroaminoac-
ridine hybrids,45 the most interesting being N-(3-(piperidin-1-
yl)propyl)-1,2,3,4-tetrahydroacridin-9-amine (25) (Fig. 4) that
showed nanomolar and selective H3 antagonism with high anti-
cholinesterase activity (95 ± 2 maximum percent inhibition of rat
brain cholinesterase; pIC50 = 7.69 ± 0.05).
Multipotent tacrine derivatives able to interact simultaneously
in the cholinergic system and muscarinic M2 receptor have been
described.46 One of these molecules is the gallamine-tacrine hybrid
26 (Fig. 4). The biochemical analysis proved that derivative 26 was
a very potent inhibitor of EeAChE with an IC50 value of about
500 pM, exhibiting EC50 values around 1 nM. The rational for this
choice was based in the well known capacity of gallamine to allos-
terically modulate muscarinic receptors47 and that tacrine is an
atypical muscarinic allosteric agent.48
Camps et al., have developed a series of donepezil-tacrine het-
erodimers.49 Donepezil is dual binding site AChE inhibitor ap-
proved for the treatment of AD. The new hybrids resulted in
potent and selective hAChE in the nM range, the most active being
compound 27 (IC50 = 0.27 ± 0.03 nM) (Fig. 4). The novel donepezil-
tacrine 27 afforded strong reductions in thioﬂavin T ﬂuorescence
among all the analyzed compounds (57% reduction), as a result
of the displacement of the ﬂuorophore at the peripheral site of
the enzyme. In agreement with this, hybrid 24 signiﬁcantly inhib-
ited the hAChE-induced aggregation of Ab1–40 by 46.1 ± 9.0% at
100 lM.
As reported above, AD is a multifactorial disease which could be
better treated by drugs acting upon more than one of its neuro-
pathological targets.50 Using the same strategy, Marco-Contelles
et al., have synthesized and evaluated a series of 1,8-naphthyridine
derivatives related to tacrine.51 The compounds were dual inhibi-
tors of both AChE and BuChE, with slight selectivity toward AChE.
Only compound CR80 (28) (Fig. 5) had signiﬁcant Ca2+-blocking
activity (20% blockade). It exhibited interesting neuroprotective
activity against oxidative stress induced by two toxic insults of
the mitochondrial chain. Tacrine 28, the best AChE inhibitor of thisO
H
N
O
N
H
H
N
N
O
( )5
Gallamine-tacrine hybrid 26
H
N
N
Cl
rid 27
d hybrids (25–27).
N N
EtO2C
NH2
CR80 (28)
N N
NH2
29
N
N
Me
AcHN
N N
NC
Me2N
NH2
30
O N
NH2
31
MeO
OH
Figure 5. New tacrine analogues reported from Marco-Contelles’ laboratory (Refs.
46–50).
A. Romero et al. / Bioorg. Med. Chem. Lett. 23 (2013) 1916–1922 1921series, was able to improve cell viability when exposed to okadaic
acid (OA)-induced s- hyperphosphorylation, and prevented OA-in-
duced protein phosphatase 2 (PP2A) inhibition, as well as protect-
ing against Ab1–42 neurotoxicity in SH-SY5Y cells. Because
compound 28 exhibited very good neuroprotective properties in
culture cells, it was found, in a more complex model based on
the rat hippocampal slice subjected to oxygen and glucose depriva-
tion (OGD) followed by reoxygenation, that tacrine was able to in-
crease cell viability in a concentration-dependent manner (1–
30 lM). It would be interesting to test derivative 28 further in
in vivo studies with AD models in order to evaluate its therapeutic
potential. In this context, the same group has also described a ser-
ies of attractive multipotent therapeutic molecules, such as 2-ami-
nopyridine- and 2-chloropyridine-3,5-dicarbonitriles,52 which act
on two biological targets that play roles in the progress of AD, such
as cholinergic dysfunction and oxidative stress. In general, these
compounds showed modest AChE and BuChE inhibition in the
micromolar range, although some derivatives were highly selective
for AChE or for BuChE. Furthermore, they afforded an important
neuroprotectant effect (30%) in the LDH/MTT test in SH-SY5Y cells
exposed to two toxic insults.
Marco-Contelles et al., also reported the synthesis and pharma-
cological analysis of tacrine analogues such as pyrazolo[3,4-
b]quinoline and benzo[b]pyrazolo[4,3-g][1,8]naphthyridine deriv-
atives,53 some of which were potent and selective AChEIs. In par-
ticular, tacrine analogue 29 (Fig. 5), the most interesting
inhibitor, was able to improve cell viability against two toxic mol-
ecules [(rotenone/oligomicin-A)-induced cell death in SH-SY5Y
cells (45% neuroprotection value)].
In the same manner, Marco-Contelles et al., synthesized new ta-
crine analogues from highly substituted 2-aminopyridine-3-carbo-
nitriles; some of these molecules, such as tacrine 3054 (Fig. 5) were
good AChE inhibitors in the nanomolar range, and quite selective
regarding the inhibition of BuChE. The neuroprotective proﬁle
shown by these compounds was only moderate.
Recently, Marco-Contelles et al., synthesized a series of very
interesting 7-aryl-9,10,11,12-tetrahydro-7H-benzo[7,8]chro-
meno[2,3-b]quinolin-8-amines as new racemic tacrine ana-
logues.55 These compounds are potent and selective inhibitors of
hAChE, in the low micromolar range. Particularly, tacrine 31
(Fig. 5) had an excellent antioxidant proﬁle as determined in the
ORAC experiment (1.47 ± 0.10 trolox equiv), crossed BBB in the
PAMPA assay, and had signiﬁcant neuroprotective effects in corti-
cal neurons against mitochondrial chain blocker-induced cell
death; and, unlike tacrine, this compound is not neurotoxic at con-
centrations lower than 50 lM, and showed less hepatotoxicity inHepG2 cells. These tacrine analogues can be considered as new
innovative therapeutic tools against AD.
Summarizing, although the present fashion in AD therapeutics
is focused on immunization procedures against Ab deposition in
senile plaques, antiphosphorylating agents to halt neuroﬁbrillary
tangle formation, and c- and b-secretase inhibitors, the above-
mentioned results with tacrine-related compounds should not be
neglected by the scientiﬁc community.56 Among others, the recent
failure in clinical phase III of semagecestat,57,58 a c-secretase inhib-
itor developed by Lilly, as well as the recent news from the Spanish
Zeltia group announcing the discontinuation of tideglusib, a GSK-
3b inhibitor developed by Noscira, targeting tau protein, are clear
examples of the state of confusion that has emerged in the medic-
inal chemistry of AD.59 Obviously, the conclusion is clear: the soun-
dest and strongest hypotheses for AD have not yet provided any
drug for the clinic. Thus, this may be the moment to revise old-fash-
ioned therapeutic strategies. In this arena, and not surprisingly,
some researchers have clearly banked on tacrine, considering that
what works, must work better. The purpose of this BMCL Digest has
been to update the most recent reports on this topic, showing the
large, latent and unexplored possibilities of this drug.
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